Brief: Novartis Receives European Commission Approval For Cosentyx
Wed 16:01
BRIEF-Novartis Receives European Commission Approval For Cosentyx Oct 21 (Reuters) - NOVARTIS AG NOVN.S:
NOVARTIS RECEIVES EUROPEAN COMMISSION APPROVAL FOR COSENTYX® IN POLYMYALGIA RHEUMATICA (PMR)
NOVARTIS AG - APPROVAL BASED ON PHASE III REPLENISH TRIAL SHOWING COSENTYX DOUBLED SUSTAINED REMISSION RATES AT WEEK 52
NOVARTIS AG - EUROPEAN COMMISSION APPROVES COSENTYX FOR ADULTS WITH PMR WITH INADEQUATE RESPONSE OR RELAPSE TO GLUCOCORTICOIDS
NOVARTIS AG - ADDITIONAL REGULATORY REVIEWS OF COSENTYX IN PMR ONGOING IN US AND JAPAN
Source text: ID:nGNE2CmcCH
Further company coverage: NOVN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant